Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 3/20 | 0.33 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4994314 | 0.83 | PLA2G10 (0.45) | MAPTCCR2F10PLA2G10ALDH1A1 | |
| SCHEMBL3584822 | 0.81 | PIK3CA (0.38) | NPC1MAPTCCR2F10PLA2G10 | |
| SCHEMBL3576486 | 0.81 | SMN1; SMN2 (0.36) | NPC1CCR2F10PLA2G10ALDH1A1 | |
| SCHEMBL3345878 | 0.80 | EGFR (0.37) | NPC1MAPTALDH1A1HPGDTSHR | |
| SCHEMBL3582637 | 0.77 | NPC1 (0.34) | NPC1CCR2 | |
| SCHEMBL3589089 | 0.75 | NPC1 (0.30) | NPC1 | |
| SCHEMBL3580573 | 0.72 | NPC1 (0.31) | NPC1HPGD | |
| SCHEMBL3483303 | 0.70 | CCR2 (0.46) | CCR2ALDH1A1TSHR | |
| SCHEMBL1746758 | 0.70 | PARP1 (0.38) | PARP1ALDH1A1HPGDTDP1MEN1 | |
| SCHEMBL2799169 | 0.68 | SLC9A1 (0.43) | NPC1MAPTCCR2F10PLA2G10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372865-B2 | Dihydropyridone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2013-02-12 | — | — | US | claimed |
| US-7816371-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2010-10-19 | — | — | US | claimed |
| US-8435990-B2 | Dihydropyrimidone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2013-05-07 | — | — | US | disclosed |
| US-8372865-B2 | Dihydropyridone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2013-02-12 | — | — | US | disclosed |
| US-20110028502-A1 | DIHYDROPYRIMIDONE AMIDES AS P2X7 MODULATORS | BROTHERTON-PLEISS CHRISTINE E | 2011-02-03 | — | — | US | disclosed |
| US-20100160373-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160373-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | P2RY1, P2RX3, P2RX1 | NPC1 2568/4885MAPT 2895/4885PARP1 1759/4885 |
| US-20110028502-A1 | DIHYDROPYRIMIDONE AMIDES AS P2X7 MODULATORS | P2RY1, P2RX7, P2RX3 | NPC1 2814/4885MAPT 4154/4885PARP1 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.